Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2012, Article ID 381724, 5 pages
Research Article

Efficacy of Eosin B as a New Antimalarial Drug in a Murine Model

1Department of Biochemistry, Pasteur Institute of Iran, Tehran 1316943551, Iran
2Department of Biochemistry, Payame Noor University, Tahran 193195, Iran
3Department of Parasitology, Pasteur Institute of Iran, Tehran 1316943551, Iran
4Department of Clinical Research, Pasteur Institute of Iran, Tehran 1316943551, Iran

Received 21 May 2012; Revised 28 August 2012; Accepted 27 November 2012

Academic Editor: Donatella Taramelli

Copyright © 2012 Zahra Zamani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The initial success of any adopted anti-infective strategy to malaria is followed by a descent due to the emergence of resistance to it. The search for new drugs and drug targets is a consistent demand in this disease. Eosin B, a common laboratory dye, is reported to have good antiparasitic properties in vitro. It was studied for its antiparasitic effect in vivo on chloroquine-sensitive Plasmodium berghei murine malaria. Eosin B was administered in 2 different doses by either the oral or parenteral route, once or twice daily to mice infected with Plasmodium berghei. Both the doses of eosin B 400 mg/kg and 800 mg/kg gave better results than the controls which were 40 mg/kg chloroquine and 100 mg/kg of arteether with significance. Percentage suppressive activity by Peter’s test of eosin B was better, though at a higher dose than both the controls. Survival rate of mice receiving the higher dose of eosin B was longer than that of the controls. When administered twice daily, the mice were fully cured after 4 days. Eosin B seems to be a promising drug exhibiting good antimalarial effects in the murine model of the disease.